He’s a hero, in every sense of the word,” Wilson County Schools wrote of Lebanon High School student-athlete Jayden Bailey in a tribute ...

Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Cancer follows a fairly standard protocol: Cells multiply out of ...

OS Therapies’ cancer vaccine, OST-HER2, has been shown to significantly improve overall survival (OS) in patients with recurrent, fully resected, pulmonary metastatic osteosarcoma after two years.

According to DelveInsight's analysis, the market size for osteosarcoma in the 7MM is expected to grow significantly by 2034. As per DelveInsight estimates, the total incident population of ...

While genetic sequencing has previously helped to uncover different subtypes of other cancers, like breast or skin cancer, for which those patients then receive targeted treatment personalised to ...

The SMAB will assist the Company in engaging with the US Food & Drug Administration (FDA) regarding the safety and efficacy of its lead immunotherapy product candidate, OST-HER2, for the treatment of ...

Osteosarcoma is a malignant neoplasm of the bone and is the most common histological form of primary bone cancer. It is most prevalent in children and young adults, as it is associated with the ...

You don’t often hear people say that losing a limb is the best thing that could have happened. But LaQuinta Haynes, 36, of Canal Winchester, says losing her leg to cancer wasn’t an ending — it was the ...

For children and young adults diagnosed with osteosarcoma, a common type of bone cancer for that age group, the odds of survival can be devastatingly low (20-30%) when the disease spreads to the lungs ...